key: cord-0838838-i60wx4nz authors: nan title: Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer date: 2021-02-03 journal: International braz j urol : official journal of the Brazilian Society of Urology DOI: 10.1590/s1677-5538.ibju.2021.02.02 sha: 9146e462acb68c127a254a5bb04e5cbd22adccba doc_id: 838838 cord_uid: i60wx4nz nan In such background, BCG is an alternative to battle agents of the most diverse natures, since the immune system is continuously tackled, especially within 2020 current context in which BCG has been challenged in clinical trials against COVID-19 as potential preventive and even therapeutic strategy to boost the immune system (13) (14) (15) . In the placebo controlled, randomized, double-blind phase III ACTIVATE study, published on August 31, 2020 in the important journal "CELL", BCG vaccination in elderly patients proved to be safe with no difference in the frequency of adverse effects, and with an 80% decrease in respiratory infections (risk ratio 0.21, p = 0.013) (16) . While onco-BCG is more profitable for manufacturers than their tuberculosis vaccine counterpart, the latter is a public health priority. From over thirty global manufacturers during the 1990s, in 2017, only 17 manufacturers worldwide kept producing BCG (17) . In the last three years, some additional manufacturers have withdrawn production. In 2011, the Food and Drug Administration (FDA) shuttered a Sanofi Pasteur's manufacturing laboratory in Toronto for health issues and mold after a flood. It never reopened. In the same year, Institute Cantacuzino, in Romania, also decided to stop BCG production. In 2014, the Danish government decided to sell the BCG vaccine production business. In 2016, Merck also experienced manufacturing issues. In the USA, Merck is currently the sole supplier of BCG (18) . The first BCG vaccine sample has arrived in Brazil in 1925, brought by the Uruguayan doctor Julio Elvio Moreau. That sample was delivered to Dr. Arlindo Raymundo de Assis in Rio de Janeiro and was called BCG Moreau (4) . Given the difficulties in bringing laboratory supplies from Europe at that time, the vaccine was initially produced with the Viscondesa de Morais culture media's, which was not the original culture media recommended by the Pasteur Institute. These adaptations were responsible for mutations in the microorganisms, and it is noteworthy the lower rate of adverse effects of this strain (19) . Since the 1930s, the Moreau strain has been maintained by the Fundação Ataulpho de Paiva (FAP), a nonprofit foundation in Rio de Janeiro, Brazil and after the 1970s the lyophilization process has been adopted. In the 1980s, the Instituto Butantan, a public research institution in São Paulo, also started to produce BCG from the Moreau-RJ strain. In 2003, the bladder cancer-targeted "onco-BCG" production also started at Instituto Butantan; however, the production was adapted at antique production laboratories that did not respect the WHO standards. After only four years, in 2007, the production of BCG ceased in São Paulo. Supply availability has been the main challenge with BCG production in Brazil as in the rest of the world, and there are several reasons for that. While vaccine development technologies have widely progressed, BCG manufacturing has remained mostly unchanged since the 1920s. Surprisingly there are no reports of significant contamination problems during the 86 years of BCG production in Brazil. Since 1992 the WHO has issued and updated the Good Manufacturing Practices for Biological Products (GMP) recommendations (20) . It is an important scientific and advisory document aiming to guide regulatory agencies and manufacturers. Nevertheless, there are some difficulties for BCG production since filtration processes cannot sterilize the BCG vaccine. For these axenic products, processing should be conducted aseptically to minimize the introduction of contaminants. For that reason, robust environmental controls and monitoring are essential to avoid contamination. In contrast to these GMP issues, suppliers and manufacturers' decisions are associated with this low-price vaccine. While the relatively low cost of BCG production makes it widely affordable, they are also associated with reduced incentives for manufacturers to enhance and invest in the production processes. WHO regional offices have tracked BCG shortages for children immunization during the last fifteen years. BCG shortages have been a problem worldwide since then, and developing countries have been even more affected (17) . If supply problems have been common for the widely applied, largely demanded, BCG vaccine, that uses a low dose (0.05 ml to 0.1 ml) per vial, it is even a bigger problem for onco-BCG that relies on higher doses (80mg). Even though there is no precise tracking for the onco-BCG shortage worldwide, supply problems have been frequent in Brazil during the last four years. In Brazil, FAP is the sole supplier. In 2016, FAP started to experience manufacturing issues with the Brazilian Health Regulatory Agency (ANVISA), as their production did not attend GMP recommendations. Non-conformities included four critic, 25 major, and 14 minor problems (21). According to FAP representatives, GMP rules are extremely difficult to be followed. Currently, GMP does not tolerate any particles in the final product. The lyophilizers must be altered for expensive ones with self-cleaning technologies. Air conditioning structures must be rebuilt; the water supply system must be reformatted. BCG is an artisanal four-month process of a potato cultivated mycobacteria that result in a low-value product. In such a context, it is not easy to implement technological processes. BCG passes through several Erlenmeyers during the cultivation process. After a 21-day cultivation period, the bacterial suspension must be repeatedly diluted for the established number of doses. The first product is evaluated according to its colony formation units (CFU) and sterility. The product must be axenic, and at least six animals must be tested for 42 days. At FAP, the solution would be a completely automated process and rebuilding new BCG manufacturing industries. Since FAP's old manufacturing unit, in São Cristóvão could not attend GMP requirements, a new unit has been under construction, in Xerém, Duque de Caxias, during the last decades. The construction of this new FAP's industry in Xerém, RJ, has been largely awaited. This unit has been under construction since 1989, costing several millions of dollars but still not working. This unit aims to respect GMP's strict rules. Furthermore, currently, there is a technology transfer agreement between FAP, in Brazil, and a Spanish institution, with a new manufacturing center being developed in Madrid to supply the European BCG market. As in many countries, in Brazil, only one strain is registered. The Moreau-RJ strain is only produced by the FAP. Another Moreau strain is produced in Poland by Biomed Lublin. At the same time of BCG shortage, bladder cancer incidence has been increasing in Brazil in the last decades, with 10.640 cases expected for each year of the 2020/21/22 triennium, while in 2018-2019, the estimate was 9.480 cases per yearc (22) . Along with the populational aging process, health care access improvement, and an increase in BC related hospitalizations make it reasonable to expect an increase of BCG requirements in the next years (22, 23) . When BCG is not available, intravesical chemotherapies or immunotherapeutics, as pembrolizumab (24), can be more rentable and less effective treatment strategies (25) , featuring as another negative incentive to BCG production. While BCG prices range between US$ 60-70 each vial (2x10 6 CFU/40mg), chemotherapies as mitomycin had their prices almost doubled recently, costing around US$ 1,000.00/ vial (18) and immunotherapeutics cost around US$ 6,000.00/vial (25) . During the last years, while the FAP production was halted, onco-BCG only became available to wealthiest Brazilians. During the frequent periods of BCG shortage in the last four years, the only alternative is to directly import, at prices as high as US$ 5,000.00/12 vials (SWOG induction protocol) (26) , instead of US$ 720.00. Additionally, the government does not acquire the onco-BCG directly from FAP anymore, and each hospital has to buy its supply through independent distributors. Right now, most patients are not receiving BCG treatment (or any treatment), and many patients are progressing to invasive disease and dying of BC much more than they should. Right now, FAP is authorized by ANVISA to sell onco-BCG vials again. However, a new audit will probably occur within the next months, with a new possible interruption of onco-BCG distribution, as GMP requirements will probably not be attended. The costs, including financial expenses, human lives, and the lack of adequate treatment, are not measured. Nevertheless, there is no doubt that treating patients with more advanced BC is significantly costlier, associated with more suffering and deaths. BCG production is a problem that has to be seriously addressed to come to a definitive solution in Brazil and all over the globe. The authors would like to acknowledge Fundação Ataulpho de Paiva -Dr. Luiz Roberto Ribeiro Castello Branco, Sr. José Luiz Gutierrez, and Instituto Butantan -Dra. Luciana Cezar de Cerqueira Leite -for their contributions. History of BCG Vaccine Issues relating to the use of BCG in immunization programmes -A discussion document BCG vaccines: WHO position paper -February Rio de Janeiro: an oral vaccine against tuberculosis--review Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors European Association of Urology Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) -2019 Update Are we following the guidelines on non-muscle invasive bladder cancer? Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes Immunometabolic Pathways in BCG-Induced Trained Immunity Non-specific effects of BCG vaccine on viral infections Targeting innate immunity for tuberculosis vaccination COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement (BATTLE). Clinicaltrials.gov 2020 Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? BCG-induced trained immunity: can it offer protection against COVID-19? Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance Supplies of a bladder cancer drug are dwindling, as patients scramble Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety World Health Organization -Good manufacturing practices for pharmaceutical -Annex 2 Fabricação de vacinas BCG e Imuno BCG é suspensa. Ascom/ANVISA. December Bladder cancer trends and mortality in the brazilian public health system Estimativa da Incidência e Mortalidade por Câncer no Brasil -2020. Instituto Nacional do Cancer José Alencar Gomes da Silva. INCA Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study None declared.